Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Importantly, the combination of giredestrant and everolimus was well tolerated
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Encouraging early detection and breaking the silence around men’s health
Subscribe To Our Newsletter & Stay Updated
